Camus Pharma was established in the year 1997, with just 4 employees on board and a small turnover of USD 150,000. The initial business was limited to Russia, where in Camus was exporting pharmaceutical raw materials and machineries. In the years to follow, the company also got into turn-key pharmaceutical projects, all of them which are running successfully today.
Camus takes turn key projects right from the conception to the factory design as per cGMP and other international certifications, supply of machineries, followed by supplies of raw materials for production. The partnership with our turn-key clients gets extended and Camus is long term pharmaceutical raw materials supplies to them.
We are also strategically involved with our long term partners and have become an important part in decision making of their growth plans.
Camus attained a big milestone with starting manufacturing of formulations in year 2006. The focus area has majorly shifted to develop and manufacture products which involve complex technologies. By sales volume, Camus crossed USD 22 million in year 2014. We are heavily investing in development of innovative products. With four highly sophisticated manufacturing sites in India, having full scale Formulation Development centres, we have successfully created a basket of very unique and innovative products, which shall bring good returns to the company.
We have currently listed 4 formulations in Russia / CIS and 17 are under registration in various countries including Russia / CIS. All these products are technically very complex and unique, as “me too” generics are nowhere in business strategy of Camus.
Also, we have successfully registered more than 45 APIs in Russia / CIS and another 18 are under registration. Key focus areas are Tuberculosis, ARV, antibiotics and Oncology.
We are fortunate to work with the best names in the industry – like Mylan, Lupin, Glenmark, Biocon, Reliance Life, Sun Pharma, Acebright, Desano, Hisun etc to name a few.
Future is bright and very positive, with big investments in innovation & technology. While we are dedicated to our current list of small molecules, enough investments are being made to be a part of Biotech revolution.
With the current set of products and the NCE that are in pipeline, and with the current set of dedicated professionals – USD 100 million in sales should be only a matter of couple of years. By year 2020, we plan to expand into the developed markets – with high quality products, backed by unique research and development.